Pipeline· August 19, 2026 · 20 min read
Avexitide LUCIDITY Phase 3: What the First GLP-1 Antagonist Means for PBH Access
By Ran Chen#Pipeline#GLP-1#Clinical Evidence
Section
Pipeline
Clinical evidence, accelerated approval, readout risk, trial design, and how pipeline signals translate into launch risk.
40 articles · Last updated
Pipeline· August 19, 2026 · 16 min read
INTerpath-001 Phase 3: Intismeran Autogene and Keytruda's Post-2028 Strategy
By Ran Chen#Pipeline#Clinical Evidence#Pivotal Trials
Pipeline· August 11, 2026 · 14 min read
Ivonescimab: the PD-1/VEGF Bispecific Ahead of Nov 2026 FDA Action
By Ran Chen#FDA Approval#Oncology#Bispecific Antibody
Pipeline· August 2, 2026 · 26 min read
In Vivo CAR-T by the Numbers 2026: $17.9B in Deals vs 23 Phase 1 Trials
By Ran Chen#CAR-T#Clinical Trials#Oncology
Pipeline· July 31, 2026 · 20 min read
mRNA Vaccines Pipeline by the Numbers (2026): 459 Clinical Trials
By Ran Chen#Clinical Trials#RNA Therapy#FDA Approval
Pipeline· July 30, 2026 · 19 min read
Companion Diagnostics (2026): FDA PMA Supplement Expansion & Device Landscape
By Ran Chen#Companion Diagnostic#FDA Approval#Oncology
Pipeline· July 29, 2026 · 25 min read
RNA Therapeutics Clinical Trials by the Numbers (2026)
By Ran Chen#RNA Therapy#Clinical Trials#FDA Approval
Pipeline· July 28, 2026 · 25 min read
Psychedelic Therapy Pipeline (2026): Lilly's $3.8B AtaiBeckley Bet & Trial Registry Data
Pipeline· July 27, 2026 · 19 min read
Genome Editing Therapy Clinical Trials by the Numbers (2026)
By Ran Chen#Clinical Trials#Gene Editing#CRISPR
Pipeline· July 26, 2026 · 18 min read